DUBLIN--(BUSINESS WIRE)--The "Global Non-Alcoholic Steatohepatitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The market was valued at US$ 729.0 Mn in 2016, and is expected to reach US$ 20,676.0 Mn by 2025, expanding at a CAGR of 46.1% from 2017 to 2025.
Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials.
The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.
Key Market Movements:
- Lucrative pipeline for NASH market with more than 20 molecules undergoing clinical trials would boost the demand for NASH market.
- Alarming rise in the diabetes and obesity prevalence would act as a driving factor for the growth of the NASH market.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Non-Alcoholic Steatohepatitis Market Analysis
Chapter 4 Global Non-Alcoholic Steatohepatitis Market Analysis, by Drug Type
Chapter 5 Global Non-Alcoholic Steatohepatitis Market, by Geography
Chapter 6 Company Profiles
- AstraZeneca plc
- Intercept Pharmaceutical Inc.
- Galmed Pharmaceuticals
- GENFIT SA
- Allergan
- Gilead Science Inc.
- Zydus Cadila
- Immuron Ltd.
- Conatus Pharmaceuticals
- Novo Nordisk
- Enzo Biochem, Inc.
- Raptor Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/v65vkp/global?w=4
